The Mid-Atlantic Technology, | March 03, 2022
The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a result of the Department of Commerce’s recent Rapid Assistance (for) Coronavirus Economic Response grant to the RAPID Manufacturing Institute, of which MATRIC is a sub-awardee.
MATRIC—applying its unique infrastructure and subject matter expertise—will lead the specialty chemical manufacturing industry with this Center of Excellence focused on accelerated process design through modular processing. Onshoring the capability to move critical pharmaceutical material manufacturing processes from concept to commercial products will enable faster response times and fewer supply chain disruptions for the Nation.
“Today, the U.S. doesn’t have the manufacturing capability to produce some key raw materials and intermediates at scale to support our pharmaceutical industry and needs. The COVID pandemic and the current global supply chain issues have taught us the importance of supply chain stability and security, and this starts with critical raw materials produced domestically, distributed with purpose, and efficiently accessed.”
MATRIC Chairman & CEO Steven B. Hedrick
“At the beginning of the COVID pandemic, we struggled to get our families and front-line healthcare workers access to necessary PPE, disinfectants and other critical equipment. I applaud MATRIC for making this exciting investment and establishing the Center for Excellence right here in West Virginia. Their broad-based chemical technology expertise will also help improve domestic Active Pharmaceutical Ingredient (API) manufacturing, at a time when onshoring our pharmaceutical supply chain is critical,” said U.S. Senator Joe Manchin (D-WV). “West Virginia’s strategic location and MATRIC’s unique skillset will play a critical role in ensuring healthcare professionals across the country can quickly and efficiently get the equipment they need to safely do their jobs.”
MATRIC is a sub-awardee of the RACER grant from the Department of Commerce to the RAPID® Manufacturing Institute (RAPID). MATRIC will collaborate with RAPID, the project leader, and with partners at Teich Process Development and Procegence.
“Through its partnership with RAPID, Teich and Procegence, MATRIC’s Center of Excellence avails our economy with choices. Choices like this afford the opportunity to source from Americans for Americans, or to selectively buy from overseas, at their discretion,” said RAPID Executive Director & Chief Technology Officer Ignasi Palou-Rivera. “Just on the horizon, the most important raw materials and intermediates for pharma will again be made available inside the United States and not be locked down by a relatively inelastic supply chain originating in nations with substantial government control.”
RACER grants are awarded by the U.S. Department of Commerce to high-impact projects designed to fund awards for research, development, and testbeds to prevent, prepare for, and respond to coronavirus.
MATRIC is the strategic innovation partner of choice that provides uncommon expertise and infrastructure to solve the most challenging science and technology problems. Focusing on the areas of chemical, energy and environmental technologies, technical engineering and advanced software technologies, MATRIC delivers innovation from concept to commercialization. We utilize our experienced and renowned staff, unique laboratory and pilot plant facilities, and flexible intellectual property models to create value for customers and investors around the world. We are an energized and expanding company that works from facilities in South Charleston and Morgantown, W.Va.
About RAPID® Manufacturing Institute
RAPID serves as a nexus between process innovation, economic development, and job creation. The technology development and educational programming we sponsor will increase energy and operational efficiencies, enhance productivity, and improve sustainability, making U.S. manufacturing in the chemical process industries (CPI) more competitive in the global market and developing the next generation workforce for these industries.
Aqemia | February 15, 2022
Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen.
Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets.
The agreement aims at building a common understanding of the performance of Aqemia’s technology and how best to apply it in drug discovery projects on different types of target proteins and diseases. It includes an upfront payment from Janssen.
“We are very happy to start working with Janssen’s teams to apply our unique technology to drug discovery projects”. He added, “This is a great opportunity for us to demonstrate the scalability and repeatability of Aqemia’s recent successes in drug discovery projects.”
Maximilien Levesque, CEO and co-founder of Aqemia
Aqemia is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates. The disruptive speed and accuracy of our technological platform enables us to scale drug discovery projects just like tech projects.
Moleculin Biotech, Inc | October 07, 2020
Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV-2, antiviral activity has now been documented for HIV, Zika and Dengue Fever.